Ameritox Launches Critical, New Synthetic Marijuana Drug Test to Help Physicians Detect Rising Use of Dangerous Designer Drugs

BALTIMORE, Oct. 3, 2012 /PRNewswire/ -- Ameritox^SM, the nation's leader in medication monitoring solutions, today announced the launch of its newest test offering for synthetic cannabinoids (also known as "synthetic marijuana," "K2," or "Spice"), a class of designer drugs intended to mimic the effects of marijuana.  Adding to its portfolio of test offerings for designer drugs, which also includes a bath salts drug test (synthetic cathinones), Ameritox's synthetic marijuana drug test now provides quantitative results for metabolites found in 15 synthetic cannabinoids that the Drug Enforcement Administration placed into Schedule I of the Controlled Substances Act this summer.

With reported side effects including paranoia, panic attacks, giddiness, and psychotic episodes, the American Association of Poison Control Centers reported that the number of calls related to synthetic marijuana and/or K2/Spice more than doubled from 2010 to 2011.

"With the rising abuse of designer drugs like synthetic cannabinoids, clinicians face an ever-increasing list of potential threats to their patients' safety – and to society's safety," said Harry Leider, M.D., chief medical officer of Ameritox.  "Today, the ability to screen for newly developed, dangerous compounds like these synthetic cannabinoids is essential. Ameritox is committed to supporting physicians with advanced urine drug monitoring technology and insights to help clinicians enhance and optimize the care of chronic pain patients."

Like other designer drugs, synthetic cannabinoids are a manufactured version of an illicit substance, created by chemists to bypass laws and provide a "legal high."  Synthetic marijuana is a mixture of herbs and spices that is typically sprayed with a synthetic compound similar to THC, the active compound in marijuana – but can be four to 100 times more potent than THC.  According to the DEA, synthetic cannabinoids are sold under a variety of names, such as K2, Spice, Skunk, Black Mamba, and Bombay Blue. They are often marketed as herbal incense or herbal smoking blends and labeled "not for human consumption."

Synthetic cannabinoids are available in head shops, tobacco stores, and over the Internet, and the U.S. government has mobilized to combat their rising abuse. In March 2011, the DEA placed five specific synthetic cannabinoids into the Schedule I section of the Controlled Substances Act, citing the move as "necessary to avoid imminent hazard to the public safety" due to high abuse potential and lack of medical use. The DEA expanded that list as part of the "Synthetic Drug Abuse Prevention Act of 2012," signed into law in July. The various branches of the U.S. military have also banned the use of synthetic cannabinoids.

For additional information, visit www.ameritox.com.

About Ameritox
Ameritox is the nation's leader in Pain Medication Monitoring Solutions^®, offering specialized laboratory testing and reporting services. Ameritox's expertise and innovative science provide physicians with insights and support to enhance and optimize the care of chronic pain patients. Ameritox offers the most thorough pain medication monitoring lab process – Rx Guardian^SM – with Rx Guardian CD^SM, the only pain medication monitoring process with a proprietary normalization algorithm and a reference database of pain patients clinically assessed for adherence. Patient results are compared against this database, helping physicians assess whether patients are taking their pain medications correctly. Monitoring through prescription drug testing helps physicians make more informed clinical decisions and manage the risks and complexities associated with prescribing pain medications. Ameritox is headquartered in Baltimore, Md. with laboratory facilities in Midland, Texas and Greensboro, N.C. Ameritox can be found online at www.ameritox.com, on Twitter @Ameritox, on Facebook at facebook.com/ameritox, and on YouTube at www.youtube.com/ameritox.

© 2012 Ameritox Ltd. All rights reserved. Ameritox, Ameritox-Medication Monitoring Solutions, Rx Guardian, Rx Guardian INSIGHT and Rx Guardian CD are trademarks of Ameritox. Other trademarks are the property of their owners.

SOURCE Ameritox

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED